TISIDB

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus, cis-Golgi network membrane; Single-pass type I membrane protein. Melanosome. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Endoplasmic reticulum-Golgi intermediate compartment membrane; Single-pass type I membrane protein. Cytoplasmic vesicle, secretory vesicle membrane Single-pass type I membrane protein Cell membrane Golgi apparatus, trans-Golgi network membrane Single-pass type I membrane protein Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Cycles between compartments of the early secretatory pathway.
Domain	PF01105 emp24/gp25L/p24 family/GOLD
Function	Involved in vesicular protein trafficking. Mainly functions in the early secretory pathway. Thought to act as cargo receptor at the lumenal side for incorporation of secretory cargo molecules into transport vesicles and to be involved in vesicle coat formation at the cytoplasmic side. In COPII vesicle-mediated anterograde transport involved in the transport of GPI-anchored proteins and proposed to act together with TMED2 as their cargo receptor; the function specifically implies SEC24C and SEC24D of the COPII vesicle coat and lipid raft-like microdomains of the ER. Recognizes GPI anchors structural remodeled in the ER by PGAP1 and MPPE1 (By similarity). In COPI vesicle-mediated retrograde transport involved in the biogenesis of COPI vesicles and vesicle coat recruitment. On Golgi membranes, acts as primary receptor for ARF1-GDP which is involved in COPI-vesicle formation. Increases coatomer-dependent GTPase-activating activity of ARFGAP2. Involved in trafficking of G protein-coupled receptors (GPCRs). Regulates F2LR1, OPRM1 and P2RY4 exocytic trafficking from the Golgi to the plasma membrane thus contributing to receptor resensitization. Involved in trafficking of amyloid beta A4 protein and soluble APP-beta release (independent of modulation of gamma-secretase activity). As part of the presenilin-dependent gamma-secretase complex regulates gamma-cleavages of the amyloid beta A4 protein to yield amyloid-beta 40 (Abeta40). Involved in organization of the Golgi apparatus.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001822 kidney development GO:0006887 exocytosis GO:0006888 ER to Golgi vesicle-mediated transport GO:0006890 retrograde vesicle-mediated transport, Golgi to ER GO:0006900 membrane budding GO:0006901 vesicle coating GO:0006903 vesicle targeting GO:0007030 Golgi organization GO:0016050 vesicle organization GO:0034205 beta-amyloid formation GO:0034248 regulation of cellular amide metabolic process GO:0035459 cargo loading into vesicle GO:0035964 COPI-coated vesicle budding GO:0042982 amyloid precursor protein metabolic process GO:0042987 amyloid precursor protein catabolic process GO:0043279 response to alkaloid GO:0045055 regulated exocytosis GO:0048193 Golgi vesicle transport GO:0048194 Golgi vesicle budding GO:0048199 vesicle targeting, to, from or within Golgi GO:0048200 Golgi transport vesicle coating GO:0048205 COPI coating of Golgi vesicle GO:0048207 vesicle targeting, rough ER to cis-Golgi GO:0048208 COPII vesicle coating GO:0050435 beta-amyloid metabolic process GO:0051259 protein oligomerization GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0072001 renal system development GO:0090114 COPII-coated vesicle budding GO:1902003 regulation of beta-amyloid formation GO:1902991 regulation of amyloid precursor protein catabolic process
Molecular Function	GO:0000149 SNARE binding GO:0019905 syntaxin binding
Cellular Component	GO:0005793 endoplasmic reticulum-Golgi intermediate compartment GO:0005798 Golgi-associated vesicle GO:0005801 cis-Golgi network GO:0012507 ER to Golgi transport vesicle membrane GO:0030133 transport vesicle GO:0030134 ER to Golgi transport vesicle GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0030137 COPI-coated vesicle GO:0030140 trans-Golgi network transport vesicle GO:0030141 secretory granule GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030662 coated vesicle membrane GO:0030667 secretory granule membrane GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane GO:0042470 melanosome GO:0042588 zymogen granule GO:0042589 zymogen granule membrane GO:0048770 pigment granule GO:0070765 gamma-secretase complex GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-446203: Asparagine N-linked glycosylation R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic R-HSA-6807878: COPI-mediated anterograde transport R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport R-HSA-5694530: Cargo concentration in the ER R-HSA-199977: ER to Golgi Anterograde Transport R-HSA-8856688: Golgi-to-ER retrograde transport R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic R-HSA-199991: Membrane Trafficking R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification R-HSA-948021: Transport to the Golgi and subsequent modification R-HSA-5653656: Vesicle-mediated transport

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-5694530: Cargo concentration in the ER
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TMED10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TMED10 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.58; FDR: 0.02150	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TMED10 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.35	0.217
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.555	0.862
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.203	0.929
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.236	0.546
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.071	0.974
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.449	0.878
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.22	0.675
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.317	0.899
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.146	0.959
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.206	0.926
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.319	0.926
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.009	0.885

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TMED10 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TMED10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TMED10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TMED10. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TMED10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TMED10 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TMED10 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TMED10
Name	transmembrane p24 trafficking protein 10
Aliases	TMP21; P24(DELTA); p24d1; p24delta1; transmembrane emp24-like trafficking protein 10 (yeast); S31I125; S31II ......
Chromosomal Location	14q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TMED10 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TMED10